COVID-19: Green light in France for vaccines adapted to omicron subvariants

The High Authority for Health recommended Tuesday the use of new vaccines developed by Pfizer and Moderna. She advises to couple this new vaccination campaign to that against seasonal flu.

by and

For the injection of an additional dose of COVVI-19 vaccine, the High Authority for Health (HAS) has recommended, in two opinions published Tuesday, September 20 , to administer one of the three vaccines adapted to omicron subvariants which were recently validated by the European Medicines Agency (EMA).

in the continuity of its previous opinions , the independent authority which guides the government in its vaccination strategy since the start of the health crisis recommends coupling this new campaign to that against the Seasonal flu which will start on October 18.

As has already been the case for several months, this additional dose is aimed at people at risk of making a severe form of the disease, that is to say all those aged 60 and over, the immunocompromised patients whatever their age, as well as those around them, pregnant women, children and adolescents at high risk, and finally professionals in the health and medico-social sectors.

In view of the epidemic recovery that has been starting for two weeks, the HAS recommends however, for people very at risk that did not receive their second dose of recall within the recommended deadlines – or three or six months according to the ‘Age and date of the latest injection or infection – to ask for a new injection now. Only 30 % of the over 60s have already received a second dose of recall, and the injection pace has been at its lowest level in six months. “Original vaccines are always effective against serious forms; if you are too far from your latest reminder, you shouldn’t wait for an additional month,” alerts Dominique Le Guludec, president of the HAS.

adaptation to the current threat

Approved vaccines on 1 er and September 12 by EMA are those developed by Pfizer-Biontech and Moderna; They are said to be “bivalents” because they target both, like all the vaccines administered so far, the original strain of Sars-Cov-2-called “Wuhan strain”-and a type of omicron subvariant. If Pfizer-Biontech was approved for two vaccines, one targeting BA.1 and the other BA.4 and BA.5, Moderna on its side has only received an authorization for its vaccine adapted to BA. 1.

These are not really new vaccines, since they use the same technology as those who have imposed themselves worldwide to fight against COVVI-19: Messenger RNA. They have simply been updated to better correspond to the current threat, born from the Omicron family, who came to France first with BA.1, then BA.2, BA.4, and now ultra hegemonic Ba. 5. They can be compared in this to the vaccines against seasonal flu which are updated each year to take into account the viruses which are most likely to circulate during the winter.

You have 47.88% of this article to read. The continuation is reserved for subscribers.

/Media reports.